“…In three, patients were assigned to receive immuno-selected CD34 + cells or placebo [38,39,77], whereas in the others, patients received unselected BM-MNCs or placebo [98,99]. The cells were mostly delivered via direct catheter-based endomyocardial injections using either the NOGA™ System [39,40,55,76,77,80,[99][100][101], or the Biocardia Helix™ catheter [53,102], or via the IC route [38,103,104]. Trans-epicardial BM-MNC implantation was performed as an adjunct to CABG surgery in four studies [105][106][107][108].…”